PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells

Cancer Letters

Volumn 253, Issue 1, 2007, Pages 97-107

  Aaltonen, Vesa ^a   Koivunen, Jussi ^a   Laato, Matti ^b   Peltonen, Juha ^a,b  

^a UNIVERSITY OF OULU   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Bladder; Carcinoma; Cell cycle; Go6976; Protein kinase C

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; DOXORUBICIN; PACLITAXEL; PROTEIN KINASE C;

ARTICLE; BLADDER CARCINOMA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; MITOSIS; MONOTHERAPY; PRIORITY JOURNAL;

CARBAZOLES; CELL DEATH; DNA DAMAGE; DOXORUBICIN; ENZYME INHIBITORS; G2 PHASE; HUMANS; INDOLES; MITOSIS; MODELS, BIOLOGICAL; PACLITAXEL; PROTEIN KINASE C-ALPHA; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 34249879271     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.01.011     Document Type: Article

References (33)

1. Chau B.N., and Wang J.Y. Coordinated regulation of life and death by RB. Nat. Rev. Cancer 3 (2003) 130-138
2. Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J. Cell. Biochem. 91 (2004) 223-231
3. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 3 (2004) 513-519
4. Blanes A., Rubio J., Martinez A., Wolfe H.J., and Diaz-Cano S.J. Kinetic profiles by topographic compartments in muscle-invasive transitional cell carcinomas of the bladder: role of TP53 and NF1 genes. Am. J. Clin. Pathol. 118 (2002) 93-100
5. Sanchez-Carbayo M., Socci N.D., Charytonowicz E., Lu M., Prystowsky M., Childs G., and Cordon-Cardo C. Molecular profiling of bladder cancer using cDNA microarrays: defining histogenesis and biological phenotypes. Cancer Res. 62 (2002) 6973-6980
6. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., and Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem. 73 (2004) 39-85
7. Nigg E.A. Mitotic kinases as regulators of cell division and its checkpoints. Nat. Rev. Mol. Cell Biol. 2 (2001) 21-32
8. Smits V.A., and Medema R.H. Checking out the G(2)/M transition. Biochim. Biophys. Acta 1519 (2001) 1-12
9. Peters J.M. The anaphase-promoting complex: proteolysis in mitosis and beyond. Mol. Cell 9 (2002) 931-943
10. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., and Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23 (2004) 2825-2837
11. Yuspa S.H. Cutaneous chemical carcinogenesis. J. Am. Acad. Dermatol. 15 (1986) 1031-1044
12. Nishizuka Y. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 9 (1995) 484-496
13. Nishizuka Y. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258 (1992) 607-614
14. Aaltonen V., Koivunen J., Laato M., and Peltonen J. Heterogeneity of cellular proliferation within transitional cell carcinoma: correlation of protein kinase C {alpha}/{beta}I expression and activity. J. Histochem. Cytochem. (2006)
15. Koivunen J., Aaltonen V., and Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett. (2005)
16. Koivunen J., Aaltonen V., Koskela S., Lehenkari P., Laato M., and Peltonen J. Protein kinase C alpha/beta inhibitor Go6976 promotes formation of cell junctions and inhibits invasion of urinary bladder carcinoma cells. Cancer Res. 64 (2004) 5693-5701
17. Biswas D.K., Cruz A.P., Gansberger E., and Pardee A.B. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. USA 97 (2000) 8542-8547
18. Biswas D.K., Dai S.C., Cruz A., Weiser B., Graner E., and Pardee A.B. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc. Natl. Acad. Sci. USA 98 (2001) 10386-10391
19. Biswas D.K., Martin K.J., McAlister C., Cruz A.P., Graner E., Dai S.C., and Pardee A.B. Apoptosis caused by chemotherapeutic inhibition of nuclear factor-kappaB activation. Cancer Res. 63 (2003) 290-295
20. Kohn E.A., Yoo C.J., and Eastman A. The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res. 63 (2003) 31-35
21. Tse A.N., and Schwartz G.K. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res. 64 (2004) 6635-6644
22. Sugiyama K., Shimizu M., Akiyama T., Tamaoki T., Yamaguchi K., Takahashi R., Eastman A., and Akinaga S. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. Int. J. Cancer 85 (2000) 703-709
23. Bunch R.T., and Eastman A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res. 2 (1996) 791-797
24. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
25. Rieger K.M., Little A.F., Swart J.M., Kastrinakis W.V., Fitzgerald J.M., Hess D.T., Libertino J.A., and Summerhayes I.C. Human bladder carcinoma cell lines as indicators of oncogenic change relevant to urothelial neoplastic progression. Br. J. Cancer 72 (1995) 683-690
26. Martiny-Baron G., Kazanietz M.G., Mischak H., Blumberg P.M., Kochs G., Hug H., Marme D., and Schachtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Go 6976. J. Biol. Chem. 268 (1993) 9194-9197
27. Gschwendt M., Dieterich S., Rennecke J., Kittstein W., Mueller H.J., and Johannes F.J. Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 392 (1996) 77-80
28. Blagosklonny M.V. Sequential activation and inactivation of G2 checkpoints for selective killing of p53-deficient cells by microtubule-active drugs. Oncogene 21 (2002) 6249-6254
29. Levesque A.A., Kohn E.A., Bresnick E., and Eastman A. Distinct roles for p53 transactivation and repression in preventing UCN-01-mediated abrogation of DNA damage-induced arrest at S and G2 cell cycle checkpoints. Oncogene 24 (2005) 3786-3796
30. Canman C.E. Replication checkpoint: preventing mitotic catastrophe. Curr. Biol. 11 (2001) R121-R124
31. Abraham R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 15 (2001) 2177-2196
32. Wang X.Q., Redpath J.L., Fan S.T., and Stanbridge E.J. ATR dependent activation of Chk2. J. Cell Physiol. 208 (2006) 613-619
33. Kohn E.A., Ruth N.D., Brown M.K., Livingstone M., and Eastman A. Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation. J. Biol. Chem. 277 (2002) 26553-26564